Thursday, November 15, 2012
Box 1. SciBX innovation summits launched.
This week, SciBX is publishing the first Roadmap
for Innovation resulting from a SciBX Summit on Innovation in Drug
Discovery & Development. In keeping with the newsletter's focus on
identifying scientific advances with translational potential and analyzing them
in their scientific and commercial context, SciBX has launched this
summit series to catalyze discussion in select areas of biomedical innovation.
The SciBX summits bring together key
opinion leaders in the translational space and focus on areas poised to reach
an inflection point. The goal is to lay out the technical challenges and
strategic opportunities for basic science, VC, biotech and pharma to lift the
field to the next level.
To bring together key players from a variety of backgrounds to discuss
these issues in depth, the SciBX editorial team
convenes a working group of four to eight key opinion leaders in advance of the
summit to develop a picture of the state of the field and help frame the
The first SciBX summit focused on macrocycles
and constrained peptides-drug platforms with the clear potential to unlock new
target space but for which there are many unanswered basic science questions.
The summit was hosted as a special session by BioPharm America at its
2012 conference in Boston. At the September meeting, the six members of the
working group were joined by an audience comprised of other leaders in the
field, including CEOs and CSOs of several macrocycle companies, representatives
from big pharmas working in the space and top academics from the Boston area
This first SciBX summit was produced with support
from the following sponsors: Aileron Therapeutics Inc.; Amgen Inc.; BioDuro LLC, a PPD LLC company; Ipsen Group; MedImmune LLC; PeptiDream Inc.; Sanofi; Sofinnova Ventures; Takeda Pharmaceutical Co. Ltd.; and Third
Following the positive reception to the summit, the SciBX editorial team has begun considering new targets,
pathways and therapeutic approaches to discuss in 2013.